中危急性髓系白血病患者缓解后移植的策略选择

[1]	Lowenberg B.Acute myeloid leukemia[J].N Engl J Med,1999,341:1051-1062.
[2]	Goldstone AH,Burnett AK,Wheatley K,et al.Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients:the results of the United Kingdom Medical Research Council AML11 trial[J].Blood,2001,98:1302-1311.
[3]	Koreth J,Schlenk R,Kopecky KJ,et al.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission:systematic review and meta-analysis of prospective clinical trials[J].JAMA,2009,301:2349-2361.
[4]	Clift RA,Buckner CD,Thomas ED,et al.The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation[J].Bone Marrow Transplantation,1987,2:243-258.
[5]	Gale RP,Büchner T,Zhang MJ,et al.HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission[J].Leukemia,1996,10:1687-1691.
[6]	Cornelissen JJ,Gratwohl A,Schlenk RF,et al.The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission:an integrated-risk adapted approach[J].Nat Rev Clin Oncol,2012,9:579-590.
[7]	Gale RE,Green C,Allen C et al.The impact of FLT3 internal tandem duplication mutant level,number,size,and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia[J].Blood,2008,111:2776-2784.
[8]	Cornelissen JJ,van Putten WL,Verdonck LF,et al.Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults:benefits for whom?[J].Blood,2007,109:3658-3666.
[9]	Vardiman JW,Thiele J,Arber DA,et al.The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes[J].Blood,2009,114:937-951.
[10]	Ley TJ,Li D,Walter MJ,et al.DNMT3A mutations in acute myeloid leukemia[J].Nat Genet,2011,43:289-290.
[11]	Peter P,Schlenk RF,Gaidzik VI,et al.IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication[J].J Clin Oncol,2010,28:3636-3643.
[12]	Nakao M,Yokota S,Iwai T,et al.Internal tandem duplication of the flt3 gene found in acute myeloid leukemia[J].Leukemia,1996,10:1911-1918.
[13]	Kottaridis P,Gale R,Frew M,et al.The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy:Analysis of 854 patients from the MRC AML 10 and 12 trials[J].Blood,2000,96:825A.
[14]	Meshinchi S,Woods WG,Stirewalt DL,et al.Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia[J].Blood,1995,64:89-94.
[15]	Levis M,Small D.FLT3:ITDoes matter in leukemia[J].Leukemia,2003,17:1738-1752.
[16]	Döhner K,Schlenk RF,Habdank M,et al.Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:interaction with other gene mutations[J].Blood,2005,106:3740-3746.
[17]	Verhaak RG,Goudswaard CS,van Putten W,et al.Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance[J].Blood,2015,106:3747-3754.
[18]	Thiede C,Koch S,Creutzig E,et al.Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)[J].Blood,2006,107:4011-4020.
[19]	Liang DC,Shih LY,Huang CF,et al.CEBPalpha mutations in childhood acute myeloid leukemia[J].Leukemia,2005,19:410-414.
[20]	Dohner H,Estey E,Grimwade D,et al.Diagnosis and management of AML in adults:2017 ELN recommendations from an international expert panel[J].Blood,2017,129:424-447.
[21]	Breems DA,Van Putten WL,Huijgens PC,et al.Prognostic index for adult patients with acute myeloid leukemia in first relapse[J].J Clin Oncol,2005,23:1969-1978.
[22]	Burnett AK,Goldstone A,Hills RK,et al.Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission[J].J Clin Oncol,2013,31:1293-1301.
[23]	Terwijn M,van Putten WL,Kelder A,et al.High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia:data from the HOVON/SAKK AML 42A study[J].J Clin Oncol,2013,31:3889-3897.
[24]	Walter RB,Gooley TA,Wood BL,et al.Impact of pretransplantation minimal residual disease,as detected by multiparametric flow cytometry,on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia[J].J Clin Oncol,2011,29:1190-1197.
[25]	Moore J,Nivison-Smith I,Goh K,et al.Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia[J].Biol Blood Marrow Transplant,2007,13:601-607.
[26]	Spierings E,Kim YH,Hendriks M,et al.Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19:1244-1253.
[27]	Kollman C,Spellman SR,Zhang MJ,et al.The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy[J].Blood,2016,127:260-267.
[28]	Bejanyan N,Weisdorf DJ,Logan BR,et al.Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation:A Center for International Blood and Marrow Transplant Research Study[J].Biol Blood Marrow Transplant,2015,21:454-459.